Skip to main content

Main menu

  • About Us
    • Leadership
    • Our Team
    • Vision, Mission and Values
    • Health and Economic Impact
    • Strategic Plan
  • Our Research
    • Research Focus
      • Brain Health
      • Cancer
      • Cardiovascular Conditions and Diseases
      • Digital Health
      • Health Policy
      • Immunity and Infectious Diseases
      • Joint Health and Mobility
      • Respiratory and Lung Health
      • Spinal Cord Injury and Rehabilitation
    • Research Centres and Programs
      • BC Centre on Substance Use
      • Centre for Aging SMART
      • Centre for Cardiovascular Innovation
      • Centre for Clinical Epidemiology and Evaluation
      • Centre for Lung Health
      • Djavad Mowafaghian Centre for Brain Health
      • Immunity and Infection Research Centre
      • International Collaboration On Repair Discoveries
      • Ovarian Cancer Research Centre
      • Vancouver Prostate Centre
      • Community Research Program
      • Emergency Medicine Research Program
      • Hematology Research Program
      • Skin Research Program
      • Other Research Focus Areas
    • News and Stories
    • Researcher Directory
    • Events and Workshops
  • Research Services
    • New to VCHRI
      • Working at VCHRI
      • Regulations and Training
      • Membership with VCHRI
    • Starting Your Project
      • Research Facilitation
      • Awards and Funding
      • Grant Management
      • Operational Approval
      • CST Cerner
    • Developing Your Project
      • Clinical Trials Administration
      • Clinical Research Unit
      • Research Privacy
      • Financial Policies and Procedures
    • Additional Support
      • Education and Training
      • Communications and Branding
      • Media Relations
      • Study Recruitment Support
      • Innovation and Industry Partnership
    • Internal Awards
    • Clinical Research
    • Innovation and Partnership
  • Participate in Research
    • Reasons to Participate
    • Participant Stories
    • Find a Study
    • Recruitment Support

User menu

  • Log in

Breadcrumb

  1. Home
  2. Our Research
  3. News and Stories
  4. Research finds encouraging trends in B.C.’s approach to severe asthma

Research finds encouraging trends in B.C.’s approach to severe asthma

Stories Sep 29, 2021 3 minutes

Fewer patients were prescribed maintenance oral corticosteroids over time, and slightly more used them periodically.

Changes in treatment approaches for people with severe asthma have ushered in a new era for this patient population, and one that could see decreased negative side effects from long-term oral corticosteroid (OCS) use, according to research led by Vancouver Coastal Health Research Institute investigator Dr. Mohsen Sadatsafavi.

“I hope that these results will encourage policymakers to continue to work towards further reducing maintenance OCS use, and for other researchers to pursue additional studies to monitor the use and impact of medications such as biologics.”

Dr. Mohsen Sadatsafavi is a principal investigator of the Respiratory Evaluation Sciences Program and associate professor in the Faculty of Pharmaceutical Sciences at the University of British Columbia. He is also a scientist with the Centre for Clinical Epidemiology and Evaluation.

Asthma is a condition without a cure. Although many patients’ symptoms will be controlled with medications, around 2.4 to 4 per cent have severe symptoms that often require treatment with inhaled, ingested or injected corticosteroids, as well as other medications. 

OCS is a well-established and trusted anti-inflammatory medication prescribed by clinicians for the maintenance treatment of severe asthma and acute attacks. However, when taken regularly—what clinicians call maintenance OCS use—over a long period of time, it can lead to negative side effects such as weight gain, high blood pressure, sleep disturbances, diabetes, cataracts and osteoporosis. 

“The effects of prolonged OCS use often become a significant source of health problems in patients with severe asthma—sometimes surpassing the burden of severe asthma itself.”

“Given these potential long-term negative consequences, reducing maintenance OCS use is an important target in the management of severe asthma,” Sadatsafavi adds. 

Sadatsafavi’s research study involved a review of the medical data of 21,144 patients with severe asthma—sourced from administrative health databases in British Columbia from the years 2000 to 2014. They found that rates of maintenance OCS dropped by an average 3.8 per cent per year over that time period.

More than 3.8 million Canadians live with asthma, according to a 2019 Asthma Canada report. Of these, around 150,000 to 250,000 individuals have severe asthma.

Sadatsafavi’s research also showed that episodic OCS use rose an average of 1.1 per cent per year. Episodic is less worrisome than regular OCS use, says Sadatsafavi, making these results an encouraging sign. 

“Episodic OCS use is okay because it provides fast treatment when symptoms get out of hand while avoiding many of the negative side effects associated with prolonged use.”

“I believe these study results demonstrate that the health care system is moving in the right direction when it comes to treating patients with severe asthma.”

Biologics and other approaches may help reduced maintenance OCS rates

Asthma is a respiratory condition caused by chronic inflammation in the airways. It narrows the bronchial tubes that connect the trachea to the lungs, restricting the passage of oxygen. The condition affects all ages: from children to older adults, and has a huge impact on people’s quality of life and ability to work, as well as on the health care system, says Sadatsafavi.

"Severe asthma is often a daily struggle for patients, the effects of which can be comparable to people undergoing treatment for cancer.”

Health Canada approved the first biologic for the treatment of severe asthma in 2005. These specialized medications are tailored to each patient, which also makes them significantly more costly than corticosteroids—around $20,000 per patient per year versus around $200 per patient per year for corticosteroids—says Sadatsafavi. 

Unlike corticosteroids, which are a broad-spectrum medication that affect cells throughout the body, biologics target antibodies that interact with certain proteins associated with inflammation, making them relatively side effect-free. A comparatively new treatment, reducing production costs could broaden their use in the years to come, Sadatsafavi predicts.

“The management of severe asthma may be improving over time in part due to more widespread and effective asthma education programs,” says Sadatsafavi. “Add to this a greater preference for prescribing inhaled corticosteroids and, perhaps, biologics—both of which come with fewer negative side effects—and we can see the potential for even greater reductions in oral corticosteroid use in the future.” 
 

Researchers

Mohsen Sadatsafavi

Related Articles

Giving voice to asthma and COPD patients

One in five new cases of childhood asthma in Canada are caused by traffic pollution

Effective mild asthma management with lower steroid doses

Share:

  • Facebook
  • Linkedin
  • Twitter
  • Email

Related Research Centres/Programs

Centre for Clinical Epidemiology and Evaluation

Get the latest research headlines in your inbox

Subscribe

Recent News and Stories

Type
Announcement

Investigator Awards 2023 Recipients

Mar 21, 2023 award
Type
Stories

Ask an expert: Is my menstrual pain normal, or could I have endometriosis?

Mar 16, 2023 women, endometriosis, preventative
Type
Stories

Honing in on precision treatments for endometriosis

Mar 14, 2023 genetics, treatment options
See more news

Get updates!

Join our newsletter mailing list to stay up to date on features and releases.

Subscribe

Quick Links

  • News and Stories
  • Careers
  • Events
  • Media Enquiries

Follow Us

  • Twitter
  • LinkedIn

© 2023 VCHRI. All rights reserved.

  • Contact
  • Privacy Policy